Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist-Reference-Cited by-同舟云学术

Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist

Published:2012-12-16 Issue:1 Volume:227 Page:1-17
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Boess Frank G.,de Vry Jean,Erb Christina,Flessner Timo,Hendrix Martin,Luithle Joachim,Methfessel Christoph,Schnizler Katrin,van der Staay F. Josef,van Kampen Marja,Wiese Welf-Burkhard,König Gerhard

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s00213-012-2933-4.pdf

Reference73 articles.

1. Addy NA, Nakijama A, Levin ED (2003) Nicotinic mechanisms of memory: effects of acute local DHβE and MLA infusions in the basolateral amygdala. Brain Res Cogn Brain Res 16:51–57

2. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674:252–259

3. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, Li J, Malysz J, Markosyan S, Marsh K, Meyer MD, Nikkel AL, Radek RJ, Robb HM, Timmermann D, Sullivan JP, Gopalakrishnan M (2007) Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27:10578–10587

4. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M (2010) In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther 334:875–886

5. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B (2007) SSR180711, a novel selective α7 nicotinic receptor partial agonist: (I) binding and functional profile. Neuropsychopharmacology 32:1–16

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future;Neuropharmacology;2020-06

2. The role of serotonin in nicotine abuse and addiction;Handbook of Behavioral Neuroscience;2020

3. Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies;Current Medicinal Chemistry;2019-10-16

4. Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein;Neurobiology of Disease;2018-09

5. Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery;Nicotine & Tobacco Research;2018-08-23